Modality
Radioligand
MOA
FcRni
Target
AHR
Pathway
STING
Crohn's
Development Pipeline
Preclinical
~Jun 2021
→ ~Sep 2022
Phase 1
~Dec 2022
→ ~Mar 2024
Phase 2
Jun 2024
→ Aug 2025
Phase 2Current
NCT06060555
266 pts·Crohn's
2024-06→2025-08·Completed
266 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-08-108mo agoPh2 Data· Crohn's
Trial Timeline
Q3Q42025Q2Q3
P2
Complet…
Catalysts
Ph2 Data
2025-08-10 · 8mo ago
Crohn's
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06060555 | Phase 2 | Crohn's | Completed | 266 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| Zanufutibatinib | Intra-Cellular | NDA/BLA | CD38 | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR | |
| Doxalemzoparlimab | Nuvalent | Approved | AHR | |
| CRS-184 | CRISPR Therapeutics | Phase 1/2 | AHR |